DCOY Decoy Therapeutics, Inc.
-
Decoy Therapeutics Reported Earnings
Wednesday, August 12, 2026 · 12:00 AM ET
Decoy Therapeutics (DCOY) reported a loss of $4.46 per share on revenue of $0.23 million for the second quarter ended June 2026. .
Decoy Therapeutics Inc. is a preclinical-stage biotechnology company which target serious unmet medical needs. The Company's initial pipeline is focused on respiratory viruses and GI cancers. Decoy Therapeutics Inc., formerly known as Salarius Pharmaceuticals Inc., is based in CAMBRIDGE, Mass.
Earnings Whisper Grade
—
Power Rating—
Reported Earnings
($4.46)
Earnings Whisper®
—
Consensus Estimate
—
Earnings Surprise
Earnings Growth—
Reported Revenue
$0.23M
Revenue Estimate
—
Revenue Surprise
Revenue Growth—